Breaking News Instant updates and real-time market news.

VCEL

Vericel

$14.37

-0.54 (-3.62%)

, FLXN

Flexion

$18.24

-0.56 (-2.98%)

04:55
10/05/18
10/05
04:55
10/05/18
04:55

Alliance for Regenerative Medicine (ARM) to hold a conference

Cell & Gene Meeting on the Mesa will be held in La Jolla, CA on October 3-5.

VCEL

Vericel

$14.37

-0.54 (-3.62%)

FLXN

Flexion

$18.24

-0.56 (-2.98%)

MDXG

MiMedx

$6.46

0.12 (1.89%)

ADAP

Adaptimmune

$14.18

0.07 (0.50%)

ABEO

Abeona Therapeutics

$11.43

-0.47 (-3.95%)

BCLI

BrainStorm

$3.75

-0.14 (-3.60%)

TIG

TiGenix

$0.00

(0.00%)

AVRO

Avrobio

$23.35

-0.1 (-0.43%)

JUNO

Acquired by CELG

$0.00

(0.00%)

BTX

BioTime

$2.22

-0.04 (-1.77%)

NITE

Nightstar Therapeutics

$17.99

-0.65 (-3.49%)

BLUE

Bluebird Bio

$140.70

-3.36 (-2.33%)

AST

Asterias

$1.15

-0.15 (-11.54%)

GSK

GlaxoSmithKline

$40.16

-0.345 (-0.85%)

WXXWY

Wuxi Biologics

$0.00

(0.00%)

CLBS

Caladrius

$5.51

0.01 (0.18%)

SGMO

Sangamo

$14.82

-0.51 (-3.33%)

BOLD

Audentes Therapeutics

$34.22

-0.76 (-2.17%)

ONVO

Organovo

$1.14

-0.02 (-1.72%)

SNY

Sanofi

$44.10

-0.51 (-1.14%)

  • 09

    Oct

  • 09

    Oct

  • 19

    Oct

  • 20

    Oct

  • 28

    Oct

  • 29

    Oct

  • 01

    Dec

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

VCEL Vericel
$14.37

-0.54 (-3.62%)

06/20/18
LEER
06/20/18
NO CHANGE
LEER
Outperform
Vericel selloff overdone, says Leerink
Leerink analyst Danielle Antalffy notes that Vericel's (VCEL) shares have been volatile for the past a few weeks and traded lower in reaction to Histogenics' (HSGX) analyst day. The analyst believes the selloff in Vericel's shares was overdone, and would use the weakness as an entry point, given her view that Histogenics' NeoCart is not a meaningful competitive threat to MACI. Vericel maintains a virtual monopoly in a highly underpenetrated articular cartilage repair market, as well as an actual monopoly in the severe burn market, she contends. Antalffy reiterates an Outperform rating on Vericel's shares.
09/05/18
PIPR
09/05/18
NO CHANGE
Target $16
PIPR
Overweight
Piper sees less competition for Vericel after Histogenics data
Piper Jaffray analyst Edward Tenthoff raised his price target for Vericel (VCEL) to $16 from $14 after Histogenics (HSGX) reported its Phase III trial of NeoCart to repair knee cartilage defects narrowly missed its primary endpoint of dual threshold responder analysis compared to microfracture in 249 patients at one-year. While Histogenics still intends to meet with the FDA to discuss biologics license application filing, Tenthoff believes a "lack of durable data removes a potential competitor" for Vericel. He continues to project $80M in sales this year for Vericel and increased his 2019 sales estimate to $96.5M. The analyst remains Overweight rating on Vericel.
07/16/18
LTCO
07/16/18
UPGRADE
Target $13
LTCO
Buy
Vericel upgraded to Buy from Neutral at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter upgraded Vericel to Buy with a $13 price target.
04/04/18
LEER
04/04/18
INITIATION
Target $15
LEER
Outperform
Vericel initiated with an Outperform at Leerink
Leerink analyst Danielle Antalffy started Vericel with an Outperform rating and $15 price target as she believes Vericel maintains a virtual monopoly in a highly underpenetrated articular cartilage repair market that could ultimately see open-ended growth longer-term.
FLXN Flexion
$18.24

-0.56 (-2.98%)

08/08/18
WELS
08/08/18
NO CHANGE
Target $39
WELS
Outperform
Flexion Q2 suggests Zilretta launch proceeding as expected, says Wells Fargo
Wells Fargo analyst David Maris kept his Outperform rating and $39 price target on Flexion, saying the company's Q2 results suggest that Zilretta sales are proceeding according to its plans and in line with his expectations. The analyst points to the management's comments that the overall response on Zilretta from physicians has been positive, adding that its unique product specific Q-code becoming effective as of this July 1st will drive sales growth in the second half of 2018.
06/28/18
06/28/18
INITIATION
Target $39

Buy
Benchmark says Zilretta can be 'best-in-class,' starts Flexion at Buy
As previously reported, Benchmark analyst Bruce Jackson initiated Flexion Therapeutics with a Buy rating and $39 price target, citing his belief that Zilretta can emerge as a "best-in-class" therapy for treating osteoarthritis knee pain. He sees peak sales potential in excess of $750M for the drug, he tells investors in his initiation note.
06/19/18
WELS
06/19/18
NO CHANGE
WELS
Outperform
Flexion to benefit from Anika Therapeutics failed Cingal study, says Wells Fargo
Wells Fargo analyst David Marris tells investors that the failed Phase 3 study by Anika Therapeutics' (ANIK) Cingal product in the treatment of knee osteoarthritis removes a potential threat from Flexion's (FLXN) Zilretta. The analyst contends that the runway for Flexion is now clear as it progresses through its early Zilretta launch phase. Marris keeps his Outperform rating on Flexion.
06/28/18
BNCH
06/28/18
INITIATION
Target $39
BNCH
Buy
Flexion initiated with a Buy at Benchmark
Benchmark started Flexion Therapeutics with a Buy rating and $39 price target.
MDXG MiMedx
$6.46

0.12 (1.89%)

02/23/18
LSCM
02/23/18
DOWNGRADE
LSCM
Hold
MiMedx downgraded to Hold from Buy at Lake Street
03/15/18
PIPR
03/15/18
NO CHANGE
PIPR
Piper suspends MiMedx rating, says DOJ review too much to digest
Piper Jaffray analyst Matt O'Brien suspended his rating and price target on MiMedx Group after the company disclosed that the Department of Justice is reviewing matters in parallel with an SEC investigation. The analyst, up until tonight, had an Overweight rating on MiMedx with an $18 price target. The stock closed the trading day down 15c to $7.12. "We have been standing by MiMedx in recent months despite numerous short selling reports on the company," O'Brien tells investors in a research note. He says, however, that the Department of Justice review, which is added to an Audit Committee and SEC investigation regarding the company's sales and distribution practices, is "simply too much for us to digest at the moment."
02/23/18
02/23/18
DOWNGRADE
Target $9

Hold
MiMedx downgraded to Hold with $9 price target at Lake Street
As previously reported, Lake Street analyst Bruce Jackson downgraded MiMedx to Hold from Buy, stating that a resolution of the investigation into current and prior period sales and distribution practices is unlikely to be swift and the shares are unlikely to outperform until the investigation is resolved. If the investigation resolves favorably, the upside potential "would be significant and he would be an aggressive buyer of the stock, but for now Jackson cut his price target on MiMedx shares to $9 from $12.
02/27/18
CHLM
02/27/18
NO CHANGE
Target $19
CHLM
Buy
Craig-Hallum maintains Buy rating, $19 price target on MiMedx
Craig-Hallum analyst Matt Hewitt noted that MiMedx denied a report that it is under investigation by the Department of Justice, stating that it is not aware of any such investigation. While stating that "it is impossible to know for certain whether any nefarious activity has ever taken place at MiMedx," Hewitt points to several events over the past year that give him confidence in the integrity of the company's financials. If the company's financials are sound, he estimate that the stock is worth two and a half times the current price, added Hewitt, who keeps a Buy rating and $19 price target on MiMedx shares.
ADAP Adaptimmune
$14.18

0.07 (0.50%)

05/10/18
RHCO
05/10/18
NO CHANGE
Target $18
RHCO
Buy
Adaptimmune price target raised to $18 from $10 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Adaptimmune to $18 and kept his Buy rating after its Q1 results. The analyst attributes his target price increase to the company's "safety review committee recommending moving to the 1BN cell dose for the MAGE-A10 program". Lawson is also basing his model on the MAGE-10 and A4 efficacy in the second half of this year, along with further NY-ESO data readout at ASCO.
09/17/18
GUGG
09/17/18
INITIATION
Target $18
GUGG
Buy
Adaptimmune initiated with a Buy at Guggenheim
Target $18.
03/16/18
03/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Atara Biotherapeutics (ATRA) initiated with a Neutral at Guggenheim. 2. Zagg (ZAGG) initiated with a Buy at DA Davidson. 3. Key Energy (KEG) initiated with a Hold at Deutsche Bank. 4. Logitech (LOGI) initiated with a Buy at DA Davidson. 5. Adaptimmune (ADAP) assumed with an Outperform at Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/04/18
LEER
06/04/18
NO CHANGE
Target $20
LEER
Outperform
Adaptimmune price target raised to $20 from $15 at Leerink
Leerink analyst Jonathan Chang raised his price target on Adaptimmune to $20 after the company presented a safety update from its two ongoing pilot studies with SPEAR T-cells targeting MAGE-A10 in non-small cell lung cancer, or NSCLC, and the triple tumor study in bladder, melanoma, and head & neck cancers at the ASCO meeting. He keeps an Outperform rating on Adaptimmune shares.
ABEO Abeona Therapeutics
$11.43

-0.47 (-3.95%)

08/17/18
SBSH
08/17/18
NO CHANGE
SBSH
Buy
Start of Phase 3 trial for EB-101 an important catalyst for Abeona, says Citi
Following the premature publication of a draft protocol for Abeona Therapeutics' EB-101 trial by the company's collaborator, Citi analyst Liav Abraham said the start of this pivotal trial represents an important near-term catalyst for the stock. The analyst, who said that the Phase I/II trial for EB-101 in recessive dystrophic epidermolysis bullosa delivered "compelling data" on wound closure at 3 and 6-months, keeps a Buy rating on Abeona shares.
06/27/18
06/27/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zimmer Biomet (ZBH) initiated with an Underperform at Bernstein. 2. Abeona Therapeutics (ABEO) initiated with a Buy at B. Riley FBR. 3. Johnson & Johnson (JNJ) initiated with a Market Perform at Bernstein. 4. T-Mobile (TMUS) initiated with an Overweight at Barclays. 5. Scynexis (SCYX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/18
LTCO
07/19/18
NO CHANGE
Target $38
LTCO
Buy
Krystal Biotech price target raised to $38 from $23 at Ladenburg
Ladenburg analyst Wangzhi Li raised his price target for Krystal Biotech (KRYS) to $38 from $23, while reiterating a Buy rating on the shares. The analyst notes that KB103 Phase 1 data in dystrophic epidermolysis bullosa is on track for Q4 report with first patients being dosed for over 2 months now. This indicates good safety so far for the first patients dosed, he contends. As only 3-6 patients are expected to be needed for the whole Phase 1 trial, the analyst believes Krystal Biotech could potentially initiate a pivotal study in 1H 2019. Abeona (ABEO) expects to start a pivotal trial later this year for its autologous personalized ex vivo gene therapy for DEB, which could help establish the regulatory endpoint and pathway for DEB and KB103, Li adds.
06/27/18
RILY
06/27/18
INITIATION
Target $26
RILY
Buy
Abeona Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico initiated Abeona Therapeutics with a Buy rating and $26 price target, citing positive early-stage clinical trial results with multiple gene therapy candidates for rare monogenic debilitating and/or fatal inherited diseases. In a research note to investors, Zavoico projected that all five of the company's product candidates could be launched by 2024 and that Abeona could receive nearly $850M in sales with positive clinical trial results and if there are no unanticipated delays.
BCLI BrainStorm
$3.75

-0.14 (-3.60%)

06/26/18
HCWC
06/26/18
NO CHANGE
Target $11
HCWC
Buy
BrainStorm 'distressed' valuation an opportunity, says H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert noted that Brainstorm announced that it will not make NurOwn available under the newly enacted "Right to Try" Act. Management deemed this impractical since the unapproved ALS treatment would only be available to those who can afford it, which would be unethical. The focus must be on completing the clinical program so the therapy can be made available to all with reimbursement, said Kolbert, who thinks Brainstorm's current valuation is "distressed" at a market capitalization below $100M despite its lead program being in a pivotal trial. He maintains a Buy rating and $11 price target on Brainstorm shares.
12/28/17
MAXM
12/28/17
NO CHANGE
Target $9
MAXM
Buy
BrainStorm fundamentals remain intact despite stock weakness, says Maxim
Maxim analyst Jason Kolbert keeps his Buy rating and $9 price target on BrainStorm Cell, saying his recent conversations with the management indicate that the company fundamentals remain unchanged with no reason for the recent weakness in the stock price. Kolbert points to the company's interim Phase III analysis on safety of NurOwn expected in June.
05/15/18
HCWC
05/15/18
INITIATION
Target $11
HCWC
Buy
BrainStorm initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert initiated BrainStorm with a Buy and $11 price target saying it is developing a first of its kind cell therapy, called NurOwn, for the treatment of Amyotrophic Lateral Sclerosis, or ALS. Kolbert said NurOwn has an established clean safety profile and convenient dosing, but also has the potential to be disease modifying, slowing down disease progression. This, combined with orphan status for a 30K U.S. and 55K EU patient market, establish real value in the company.
TIG TiGenix
$0.00

(0.00%)

01/16/18
BTIG
01/16/18
DOWNGRADE
BTIG
Neutral
TiGenix downgraded to Neutral from Buy at BTIG
01/08/18
ADAM
01/08/18
DOWNGRADE
Target $43
ADAM
Hold
TiGenix downgraded to Hold from Buy at Canaccord
Canaccord analyst John Newman downgraded TiGenix to Hold from Buy after the company announced an agreement to be acquired by Takeda in an all cash buyout at $42.80 per ADS.
01/16/18
BTIG
01/16/18
DOWNGRADE
BTIG
Neutral
TiGenix downgraded at BTIG to Neutral on valuation
As noted earlier, BTIG analyst Timothy Chiang downgraded TiGenix (TIG) to Neutral from Buy, saying the run-up of 81% year to date in the stock price has exceeded his target and warrants a move to the sidelines. Chiang believes that the acquisition offer by Takeda (TKPYY) will pass the required regulatory review of TiGenix lead product Alofisei in the E.U., adding that there is now less than 5% difference in the stock price relative to the Takeda offer.
AVRO Avrobio
$23.35

-0.1 (-0.43%)

09/17/18
HCWC
09/17/18
INITIATION
Target $47
HCWC
Buy
Avrobio initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started Avrobio with a Buy rating and $47 price target. The status quo in the treatment of lysosomal storage disorders is likely to be disrupted, Chattopadhyay tells investors in a research note. The analyst recommends being opportunistic on pullbacks and building a position in the name.
07/16/18
COWN
07/16/18
INITIATION
COWN
Outperform
AvroBio initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated AvroBio with an Outperform rating citing its four programs that have been generated from its lentiviral gene therapy platform for lysomal storage diseases. The analyst expects the company to create long-term value with its gene therapy programs.
07/16/18
MSCO
07/16/18
INITIATION
Target $37
MSCO
Overweight
AvroBio initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz initiated AvroBio (AVRO) with an Overweight rating and $37 price target, noting that its a unique gene therapy company that has human clinical data for one of its programs at the time of its initial public offering. He points to Novartis' (NVS) recent acquisition of AveXis for $8.7B, or an 88% premium, as an illustration of the substantial interest in and valuation premium put into many names in the gene therapy space.
07/16/18
WELS
07/16/18
INITIATION
Target $40
WELS
Outperform
AvroBio initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started AvroBio with an Outperform rating and $40 price target based on what he views as a differentiated capability in applying lentiviral-based gene therapy, a proven platform with curative potential, to lysosomal storage diseases, proof-of-mechanism afforded by existing LSD treatment approaches including enzyme replacement therapy and allogeneic hematopoietic stem cell transplant, encouraging initial phase 1 data in Fabry disease demonstrating rapid, robust, and sustained enzyme expression, and a leverageable platform that extends to multiple LSDs with established markets and multibillion dollar opportunities.
JUNO Acquired by CELG
$0.00

(0.00%)

04/24/18
JEFF
04/24/18
NO CHANGE
Target $27
JEFF
Buy
Epizyme shares will bounce back, says Jefferies
Jefferies analyst Michael Yee says that while the partial clinical hold is a bad headline, shares of Epizyme (EPZM) will bounce back like Cellectis (CLLS), Juno and others did when they modified the protocol and trial brochures to get back up and running. After speaking to management, Yee thinks Epizyme's partial clinical hold will be lifted in a few months. Until then, however, the shares could be in the penalty box, the analyst tells investors in a research note. He keeps a Buy rating on Epizyme with a $27 price target.
03/08/18
BTIG
03/08/18
NO CHANGE
Target $250
BTIG
Buy
Bluebird Bio price target raised to $250 from $177 at BTIG
BTIG analyst Dane Leone raised his price target for Bluebird Bio to $250 to reflect recent acquisitions of peer companies, meetings with the management team, and conversations at the American Society for Blood and Marrow Transplantation conference. Following the acquisition of Juno, Bluebird stands as the leading independent company with integrated genetic and cell therapy capabilities, Leone tells investors in a research note. He believes, however, that Bluebird management has no interest in selling the company within the near term. The analyst says his new price target reflects the company's long-term value proposition. Leone keeps a Buy rating on Bluebird Bio.
01/29/18
WELS
01/29/18
NO CHANGE
Target $23
WELS
Outperform
Iovance Biotherapeutics price target raised to $23 from $17.50 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics (IOVA) to $23 following feedback from a "prominent cell therapy expert" late last week. The expert described expanding capacity for Gilead's (GILD) Yescarta, skepticism on Celgene (CELG) and Juno Therapeutics' (JUNO) claims around broad outpatient CAR-T opportunity for JCAR17, and a preference for tumor infiltrating lymphocyte therapeutics from Iovance for solid tumors over T-Cell receptor therapeutics being developed by a large number of companies, Birchenough tells investors in a research note. He reiterates Outperform ratings on both Iovance and Gilead.
03/07/18
LEHM
03/07/18
NO CHANGE
Target $59
LEHM
Overweight
Crispr Therapeutics price target raised to $59 from $29 at Barclays
Barclays analyst Gena Wang raised her price target for Crispr Therapeutics (CRSP) to $59 citing the company's technology platform and pipeline value. Several recent events, including the acquisitions of Kite and Juno and Sangamo (SGMO) collaboration with Gilead (GILD), validated the value of cell therapy and the potential of gene-editing technologies to serve as a powerful tool in developing next-generation products, Wang tells investors in a research note. She sees "strong upside potential" in Crispr shares and keeps an Overweight rating on the name.
BTX BioTime
$2.22

-0.04 (-1.77%)

02/02/18
LSCM
02/02/18
INITIATION
Target $8
LSCM
Buy
BioTime initiated with a Buy at Lake Street
Lake Street analyst Bruce Jackson started BioTime with a Buy rating and $8 price target. The company may appear complex given its interdependent corporate structure, but there is reward for investors who can recognize the value creation underway at both BioTime and its minority investments, Jackson tells investors in a research note.
NITE Nightstar Therapeutics
$17.99

-0.65 (-3.49%)

09/24/18
HCWC
09/24/18
NO CHANGE
Target $8
HCWC
Buy
Nightstar data a de-risking event for Applied Genetic, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis views Nightstar Therapeutics' (NITE) positive preliminary safety and efficacy data originated from its Phase 1/2 trial, which is testing NSR-RPGR for the treatment of X-linked retinitis pigmentosa in patients with the RPGR mutation, as a de-risking event for Applied Genetic's (AGTC) program. The Nightstar data represent "significant validation" for the ongoing Applied Genetic Phase 1/2 trial in XLRP in partnership with Biogen (BIIB), Pantginis tells investors in a research note. He keeps a Buy rating on the shares with an $8 price target.
09/24/18
BMOC
09/24/18
NO CHANGE
Target $41
BMOC
Outperform
Nightstar Therapeutics price target raised to $41 from $30 at BMO Capital
BMO Capital analyst Matthew Luchini raised his price target on Nightstart to $41 and kept his Outperform rating, saying he is adding to his model the impact of NSR-RPGR disclosed last week in the presentation of early dose escalation Phase I/II data. The analyst notes says the improvements in microperimetry cohorts 3-5 "provide preliminary proof-of-concept and support initiation of the expansion study planned for Q4", adding that XLRP could achieve peak sales of about $675M.
09/24/18
LEER
09/24/18
NO CHANGE
Target $35
LEER
Outperform
Nightstar Therapeutics price target raised to $35 from $30 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Nightstar Therapeutics to $35 from $30 saying he is more positive on its pipeline after reviewing data presented at EURETINA and speaking with management about their NSR-RPGR program. The analyst reiterates an Outperform rating on the shares.
09/24/18
JEFF
09/24/18
NO CHANGE
Target $25
JEFF
Buy
Nightstar should trade higher on 'promising' data, says Jefferies
Shares of Nightstar Therapeutics should trade higher after presenting positive first data for its new XLRP gene therapy that demonstrates multiple "responders" of vision improvement, solid durability out to six months, and good safety, Jefferies analyst Michael Yee tells investors in a research note. He believes the treatment has promising trends of efficacy and is now expanding to a larger Phase II enrollment. Nightstar now looks to have two attractive retinal gene therapy drugs with lead pivotal Phase III choroideremia enrolling on track, plus a Phase II expanding for the new XLRP blindness program this weekend which hasn't been in consensus estimates, Yee contends. He keeps a Buy rating on the shares.
BLUE Bluebird Bio
$140.70

-3.36 (-2.33%)

09/17/18
GUGG
09/17/18
INITIATION
Target $164
GUGG
Neutral
Bluebird Bio initiated with a Neutral at Guggenheim
Target $164.
09/21/18
GSCO
09/21/18
DOWNGRADE
Target $288
GSCO
Buy
Bluebird Bio downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter removed Bluebird Bio from his firm's Americas Conviction List but keeps a Buy rating on the name with a $288 price target. The rating change is is not driven by concerns around Bluebird's pipeline execution or emerging competitive threats, Richter tells investors in a research note. The analyst just believes appreciation of key aspects of his investment thesis are better reflected in the shares at current valuation levels.
09/21/18
09/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bluebird Bio (BLUE) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Salveen Richter saying rating change is is not driven by concerns around Bluebird's pipeline execution or emerging competitive threats. The analyst just believes appreciation of key aspects of his investment thesis are better reflected in the shares at current valuation levels. 2. Venator Materials (VNTR) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas saying he believes lower prices and higher raw material costs for TiO2, coupled with higher capital expenditures, diminishes Venator's free cash flow outlook. 3. Antero Resources (AR) downgraded to Market Perform from Outperform at BMO Capital with analyst Phillip Jungwirth citing valuation. 4. New Age Beverages (NBEV) downgraded to Hold from Buy at Maxim. 5. Rowan Companies (RDC) downgraded to Hold from Buy at HSBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/18
WELS
09/11/18
NO CHANGE
WELS
Amgen's AMG420 risk overstated, says Wells Fargo
Wells Fargo analyst Jim Birchenough believes shares of Bluebird Bio (BLUE) have been under pressure on concerns regarding potential competitive risk to BCMA CAR T therapeutic bb2121 from Amgen's (AMGN) bispecific T cell engager AMG420. The analyst highlights that AMGN420 is a continuous IV infusion and in his opinion not a viable competitor to a single bb2121 cell therapy dose, particularly given long-term durability of response with bb2121. Further, he notes that Amgen's approved first generation CD19 bispecific engager, BLINCYTO, is dosed as a continuous IV for 4 weeks out of every 6 and achieved only $175M in sales in 2017 following 2015 approval. He does not view this dose schedule for first generation bispecific T cell engagers as commercially viable in a more chronic cancer. Additionally, the analyst points out that Affimed (AFMD) also has a preclinical BCMA engager AFM26, established proof-of-concept data for CD30 bispecific AFM13, and upcoming proof-of-concept data for CD19 bispecific AFM11.
AST Asterias
$1.15

-0.15 (-11.54%)

08/10/18
RAJA
08/10/18
DOWNGRADE
RAJA
Market Perform
Asterias downgraded to Market Perform from Outperform at Raymond James
02/22/18
02/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Loxo Oncology (LOXO) initiated with an Outperform at Oppenheimer. 2. Asterias (AST) initiated with a Buy at B. Riley FBR. 3. Viveve (VIVE) initiated with a Buy at Empire. 4. Panhandle Oil & Gas (PHX) initiated with a Buy at Roth Capital. 5. Aduro Biotech (ADRO) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/22/18
RILY
02/22/18
INITIATION
Target $6
RILY
Buy
Asterias initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Asterias Biotherapeutics with a Buy rating and $6 price target. The analyst believes the company has shown "promising signs of efficacy" in spinal cord and cancer.
GSK GlaxoSmithKline
$40.16

-0.345 (-0.85%)

09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
08/30/18
08/30/18
DOWNGRADE

GlaxoSmithKline downgraded to Hold from Buy at Liberum
Liberum analyst Roger Franklin downgraded GlaxoSmithKline to Hold while raising his price target for the shares to GBP 17 from GBP 16.30. The analyst believes the company's improved research and development is now priced into the shares and he sees less upside going forward.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
08/15/18
RBCM
08/15/18
NO CHANGE
RBCM
Outperform
RBC says Gilead weakness on CMO leaving, Glaxo data a buying opportunity
RBC Capital analyst Brian Abrahams believes Gilead's (GILD) weakness is potentially due to data from GlaxoSmithKline's (GSK) ATLAS trial and last night's announcement of the departure of its CMO. However, he does not see either as a major fundamental concern and would use the weakness in Gilead shares as a buying opportunity. Feedback he has received from doctors is that injectables like Glaxo's could be used in a select number of patients, but he does not see a major impact on Gilead's HIV franchise near- or long-term from this product, Abrahams said. On the CMO departure, the analyst said that the company clarified that this is "completely unrelated" to the recently-announced CEO transition, so he does not see this reflecting any major structural issue. Abrahams keeps an Outperform rating on Gilead shares, which are down over 3% to $74.82 in afternoon trading.
WXXWY Wuxi Biologics
$0.00

(0.00%)

05/28/18
DBAB
05/28/18
INITIATION
DBAB
Buy
Wuxi Biologics initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Jack Hu started Wuxi Biologics with a Buy rating and HKD 100 price target.
01/04/18
JPMS
01/04/18
INITIATION
JPMS
Overweight
Wuxi Biologics initiated with an Overweight at JPMorgan
JPMorgan analyst Leon Chik started Wuxi Biologics with an Overweight rating and HK$55 price target.
CLBS Caladrius
$5.51

0.01 (0.18%)

03/07/18
HCWC
03/07/18
NO CHANGE
Target $12
HCWC
Buy
Caladrius price target raised to $12 from $7 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Caladrius Biosciences (CLBS) to $12 after the company acquired from Shire (SHPG) an exclusive worldwide license to data and regulatory filings for a late-stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina. The deal "significantly enriches" Caladrius' existing pipeline and should provide an "additional attractive shot on goal" in the coming years, Selvaraju tells investors in a research note. He increased his valuation of the company to $120M from $60M and reiterates a Buy rating on the shares.
09/10/18
HCWC
09/10/18
NO CHANGE
Target $15
HCWC
Buy
Caladrius price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Caladrius Biosciences to $15 saying the shares are still undervalued following last month's Q2 results. The substantially lower than expected net loss "underscores prudent financial management," Selvaraju tells investors in a research note. The T-Rex Study Phase 2 trial of CLBS03 in Type 1 diabetes is slated to report top-line data in Q1 of 2019, the analyst points out. If the CLBS03 data are positive, the company could secure a partnership with a larger pharmaceutical firm for late-stage development, he contends. Selvaraju reiterates a Buy rating on Caladrius.
SGMO Sangamo
$14.82

-0.51 (-3.33%)

06/20/18
BOFA
06/20/18
INITIATION
Target $24
BOFA
Buy
Sangamo initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Qian Wang initiated Sangamo with a Buy and $24 price target saying it has one of the most advanced pipelines in the clinic using zinc finger protein technology. Wang said Sangamo has established partnerships with major players that validates the technology and expects multiple catalysts throughout 2H 2018 and beyond.
09/06/18
JEFF
09/06/18
NO CHANGE
Target $28
JEFF
Buy
Sangamo selloff yesterday an overreaction, says Jefferies
Jefferies analyst Maury Raycroft views the selloff yesterday in shares of Sangamo Therapeutics as an overreaction. Though Street expectations "were misaligned" heading into the initial genome-editing Mucopolysaccharidosis Type II data reported yesterday, initial results demonstrated success and set the stage for additional validating data, Raycroft tells investors in a research note. He believes Sangamo's platform is "robust/valuable" and points out that the company's expects up to five pivotal programs in next few years. The analyst keeps a Buy rating on the shares with a $28 price target.
04/10/18
JEFF
04/10/18
NO CHANGE
JEFF
Jefferies sees value in Abeona, Sangamo, Ultragenyx after AveXis deal
Jefferies analyst Maury Raycroft believes Novartis' (NVS) acquisition of AveXis (AVXS) provides additional validation for the progress and potential of gene therapy. The deal brings attention to Abeona Therapeutics (ABEO) specifically, based on the company's use of AAV9, which is the same vector AveXis has been evaluating with its lead program AVXS-101, Raycroft tells investors in a research note. He thinks yesterday's takeover puts an updated value on gene therapy, implying long-term potential and "sufficient de-risking has occurred." The analyst feels the premium paid for AveXis shows value in Abeona, Sangamo (SGMO) and Ultragenyx (RARE).
08/09/18
JEFF
08/09/18
NO CHANGE
Target $28
JEFF
Buy
Jefferies sees 'excellent entry point' for Sangamo after data
Jefferies analyst Maury Raycroft believes current share levels offer an "excellent entry point" into Sangamo Therapeutics following the company's hemophilia A data. While early, the data is "looking good," Raycroft tells investors in a research note. He believes Sangamo is aiming for best-in-class versus first-to-market. Two clinical catalysts for Sangamo have now been substantially de-risked, Raycroft contends. He recommends buying the stock and keeps a $28 price target for the shares.
BOLD Audentes Therapeutics
$34.22

-0.76 (-2.17%)

10/04/18
PIPR
10/04/18
NO CHANGE
Target $45
PIPR
Overweight
Piper sees much larger market potential for Audentes' AT132
A recent article in Neuromuscular Disorders suggests that the global incidence and prevalence of X-linked myotubular myopathy and other centronuclear myopathies may be much higher than previously thought, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst says that due to advancements in diagnostic approaches that can identify patients with milder disease and updated patient survival estimates, the pool of patients eligible for Audentes Therapeutics ' AT132 treatment may be three-times greater than he currently models. He notes that AT132 represents $13 per share in his sum-of-parts analysis and that this would increase with higher XLMTM incidence and prevalence assumptions. Raymond continues to like the setup for the the stock and keeps an Overweight rating on Audentes Therapeutics with a $45 price target.
08/20/18
SBSH
08/20/18
INITIATION
Target $40
SBSH
Buy
Audentes Therapeutics initiated with a Buy at Citi
Citi initiated Audentes Therapeutics with a Buy and $40 price target.
08/21/18
SBSH
08/21/18
INITIATION
Target $40
SBSH
Neutral
Audentes Therapeutics initiated with a Neutral at Citi
Citi analyst Mohit Bansal initiated Audentes Therapeutics with Neutral and $40 price target saying valuation reflects much of the company's opportunities.
09/06/18
RILY
09/06/18
INITIATION
Target $20
RILY
Sell
Audentes Therapeutics initiated with a Sell at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Audentes Therapeutics with a Sell rating and $20 price target. A modest market size opportunity and clinical data suggest the shares are overvalued, Kumar tells investors in a research note.
ONVO Organovo
$1.14

-0.02 (-1.72%)

11/10/17
RAJA
11/10/17
DOWNGRADE
RAJA
Market Perform
Organovo downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Reni Benjamin downgraded Organovo to Market Perform citing management's lowering of 2018 revenue guidance and uncertainty the company's disease modeling business. The analyst removed his price target for the shares.
SNY Sanofi
$44.10

-0.51 (-1.14%)

09/13/18
STFL
09/13/18
INITIATION
Target $127
STFL
Buy
AnaptysBio resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of AnaptysBio (ANAB) with a Buy rating and $127 price target, stating that he is positively biased heading into etokimab's Phase 2a results for severe eosinophilic asthma, given his view on the strong rationale for the inhibition of IL-33, etokimab's meaningful reduction of eosinophils seen in an earlier Phase 2a study, and the success of Regeneron (REGN) and Sanofi's (SNY) Dupixent.
09/10/18
BOFA
09/10/18
UPGRADE
BOFA
Buy
Sanofi upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Graham Parry upgraded Sanofi to Buy from Neutral saying the company is approaching an inflection in growth from new products, mainly Dupixent, atopic, dermatitis, while diabetes becomes less of a headwind. Parry believes sales and earnings growth will accelerate to 7% from 4% in through 20-2023E and views valuation as undervaluing growth.
09/14/18
LSCM
09/14/18
NO CHANGE
Target $90
LSCM
Buy
Apple Watch more likely a positive for BioTelemetry, says Lake Street
After spending time with Joe Capper and Heather Getz, CEO and CFO of BioTelemetry (BEAT), Lake Street analyst Brooks O'Neil senses that Apple's (AAPL) Watch Series 4, which includes a built-in electrocardiogram, is more likely a positive for BioTelemetry "than a buzzer sounding a flat-line for the company's future." BioTelemetry remains the leading cardiac monitoring company and this is likely to continue for the foreseeable future, O'Neil tells investors in a research note. He points out the company has a partnership with Apple in cardiac monitoring and with Sanofi (SNY) and Alphabet (GOOG) in diabetes. The analyst's guesses that its partnership is one element giving BioTelemetry management comfort in evaluating the role Apple might play in the company's future. O'Neil reaffirms a Buy rating on the shares with a $90 price target.
10/01/18
PIPR
10/01/18
NO CHANGE
PIPR
Overweight
Piper keeps Overweight on Regeneron after Libtayo approval
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) after Friday's FDA approval of Libtayo in cutaneous squamous cell carcinoma. Timing is about a month ahead of the late-October FDA action date for Regeneron/Sanofi's (SNY) PD-1 inhibitor, but a positive decision was expected given the drug's "compelling data" in advanced CSCC, Raymond tells investors in a research note. While Libtayo will enter the market as the sixth approved PD-(L)1 inhibitor and third approved PD-1 agent, Raymond thinks readouts from the ongoing development program in other indications such as first-line non-small-cell lung carcinoma may make the case for moderate Libtayo uptake. However, he continues to like the set-up for Regeneron shares going forward.

TODAY'S FREE FLY STORIES

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

16:40
10/19/18
10/19
16:40
10/19/18
16:40
General news
Breaking General news story on MSCI Italy Index, SPDR S&P 500 ETF Trust, S&P 500 »

Moody's cuts Italy…

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$2.93

-0.02 (-0.68%)

16:39
10/19/18
10/19
16:39
10/19/18
16:39
Hot Stocks
Breaking Hot Stocks news story on Astrotech »

Winn Interests reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$15.43

-1.075 (-6.52%)

16:38
10/19/18
10/19
16:38
10/19/18
16:38
Conference/Events
CytomX Therapeutics to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ICLK

iClick Interactive Asia

$3.41

(0.00%)

16:36
10/19/18
10/19
16:36
10/19/18
16:36
Hot Stocks
Breaking Hot Stocks news story on iClick Interactive Asia »

LIM Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGLS

Tecnoglass

$9.72

(0.00%)

16:35
10/19/18
10/19
16:35
10/19/18
16:35
Syndicate
Breaking Syndicate news story on Tecnoglass »

Tecnoglass files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

16:30
10/19/18
10/19
16:30
10/19/18
16:30
Options
Preliminary option volume of 24.7M today »

Preliminary option volume…

OXM

Oxford Industries

$81.36

-1.68 (-2.02%)

16:28
10/19/18
10/19
16:28
10/19/18
16:28
Conference/Events
Oxford Industries management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HELE

Helen of Troy

$120.52

0.31 (0.26%)

16:26
10/19/18
10/19
16:26
10/19/18
16:26
Conference/Events
Helen of Troy management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CGA

China Green

$0.74

0.0584 (8.57%)

16:21
10/19/18
10/19
16:21
10/19/18
16:21
Hot Stocks
China Green receives NYSE notice regarding late Form 10-K filing »

China Green Agriculture…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
10/19/18
10/19
16:20
10/19/18
16:20
Options
Closing CBOE SPX and VIX Index summary for October 19th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:20
10/19/18
10/19
16:20
10/19/18
16:20
Conference/Events
Morgan Stanley energy analyst to hold an analyst/industry conference call »

Refining & Canadian…

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

16:20
10/19/18
10/19
16:20
10/19/18
16:20
Hot Stocks
Bristol-Myers updates on use of Opdivo and Yervoy in first-line lung cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
10/19/18
10/19
16:17
10/19/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNGO

Bionano Genomics

$6.98

0.08 (1.16%)

16:17
10/19/18
10/19
16:17
10/19/18
16:17
Hot Stocks
Bionano Genomics and GrandOmics partner to offer genetic test for FSHD in China »

Bionano Genomics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEP

Holly Energy Partners

$30.73

-0.2 (-0.65%)

16:16
10/19/18
10/19
16:16
10/19/18
16:16
Hot Stocks
Holly Energy Partners raises quarterly distribution to 66.5c from 66c per unit »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

SES

Synthesis Energy Systems

$1.70

-0.075 (-4.23%)

16:16
10/19/18
10/19
16:16
10/19/18
16:16
Hot Stocks
Synthesis Energy Systems receives non-compliance letter from Nasdaq »

Synthesis Energy Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
10/19/18
10/19
16:16
10/19/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACET

Aceto

$2.17

(0.00%)

16:11
10/19/18
10/19
16:11
10/19/18
16:11
Syndicate
Breaking Syndicate news story on Aceto »

Aceto files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$26.71

0.13 (0.49%)

, XLE

Energy Select Sector SPDR

$71.62

-0.55 (-0.76%)

16:09
10/19/18
10/19
16:09
10/19/18
16:09
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX) was…

XLF

Financial Select Sector

$26.71

0.13 (0.49%)

XLE

Energy Select Sector SPDR

$71.62

-0.55 (-0.76%)

XLI

Industrial Select Sector SPDR

$73.32

-0.16 (-0.22%)

SPY

SPDR S&P 500 ETF Trust

$276.77

0.44 (0.16%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$84.97

7.47 (9.64%)

, AXP

American Express

$106.95

4.09 (3.98%)

16:07
10/19/18
10/19
16:07
10/19/18
16:07
General news
Fly Intel: Wall Street's top stories for Friday »

Stocks opened in positive…

PYPL

PayPal

$84.97

7.47 (9.64%)

AXP

American Express

$106.95

4.09 (3.98%)

CLF

Cleveland-Cliffs

$11.07

-0.4 (-3.49%)

AIG

AIG

$47.28

-1.345 (-2.77%)

DWDP

DowDuPont

$57.48

-1.12 (-1.91%)

AAPL

Apple

$220.01

4.03 (1.87%)

SKX

Skechers

$29.75

3.7 (14.20%)

PG

Procter & Gamble

$87.65

7.335 (9.13%)

EBAY

eBay

$28.85

-2.71 (-8.59%)

OZK

Bank OZK

$25.37

-9.48 (-27.20%)

LLNW

Limelight Networks

$4.22

-0.85 (-16.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 01

    Nov

  • 05

    Nov

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 03

    Mar

MSBI

Midland States

$28.26

-0.67 (-2.32%)

16:07
10/19/18
10/19
16:07
10/19/18
16:07
Hot Stocks
Midland States announces CEO succession plan »

Midland States Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

VALU

Value Line

$25.00

(0.00%)

16:05
10/19/18
10/19
16:05
10/19/18
16:05
Hot Stocks
Value Line authorizes repurchase of $2M in common stock »

Value Line board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVG

Navigators

$69.31

0.1 (0.14%)

, HIG

Hartford Financial

$46.71

0.2 (0.43%)

16:05
10/19/18
10/19
16:05
10/19/18
16:05
Hot Stocks
Navigators: HSR waiting period expires for merger with Hartford subsidiary »

The Navigators Group…

NAVG

Navigators

$69.31

0.1 (0.14%)

HIG

Hartford Financial

$46.71

0.2 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GBL

GAMCO Investors

$21.03

-0.1 (-0.47%)

, TPCO

Tribune Publishing

$15.27

-0.03 (-0.20%)

16:05
10/19/18
10/19
16:05
10/19/18
16:05
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, Tribune Publishing »

Gabelli reports 5.47%…

GBL

GAMCO Investors

$21.03

-0.1 (-0.47%)

TPCO

Tribune Publishing

$15.27

-0.03 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPRX

Five Prime

$14.30

0.05 (0.35%)

16:02
10/19/18
10/19
16:02
10/19/18
16:02
Hot Stocks
Breaking Hot Stocks news story on Five Prime »

Great Point Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.